Laurie W Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laurie W Smith has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Coldman
British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada
1 shared publication - Darrel Cook
Clinical Prevention Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada
1 shared publication - Dirk van Niekerk
Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
1 shared publication - Eduardo Luis Franco
Division of Cancer Epidemiology, McGill University, Montreal, QC H4A 3T2, Canada
1 shared publication - Gavin Stuart
Faculty of Medicine, University of British Columbia, Vancouver, Canada. 4
1 shared publication - Gina Ogilvie
Women's Health Research Institute Vancouver British Columbia Canada
1 shared publication
Latest Publications
- Open Access
- 24 March 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 111
A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
In the HPV FOCAL trial, we will establish the efficacy of hr-HPV DNA testing as a stand-alone screening test followed by liquid based cytology (LBC) triage of hr-HPV-positive women compared to LBC followed by hr-HPV triage with ≥ CIN3 as the outcome. HPV-FOCAL is a randomized, controlled, three-armed study over a four year period conducted in British Columbia. It will recruit 33,000 women aged 25-65 through the province's population based cervical cancer screening program. Control arm: LBC at entry and two years, and combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases; Two Year Safety Check arm: hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives; Four Year Intervention Arm: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive cases To date, 6150 participants have a completed sample and epidemiologic questionnaire. Of the 2019 women enrolled in the control arm, 1908 (94.5%) were cytology negative. Women aged 25-29 had the highest rates of HSIL (1.4%). In the safety arm 92.2% of women were hr-HPV negative, with the highest rate of hr-HPV positivity found in 25-29 year old women (23.5%). Similar results were obtained in the intervention arm HPV FOCAL is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer within a population-based cervical cancer screening program. International Standard Randomised Controlled Trial Number Register, ISRCTN79347302
- 24 March 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 111
Open AccessA randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
In the HPV FOCAL trial, we will establish the efficacy of hr-HPV DNA testing as a stand-alone screening test followed by liquid based cytology (LBC) triage of hr-HPV-positive women compared to LBC followed by hr-HPV triage with ≥ CIN3 as the outcome. HPV-FOCAL is a randomized, controlled, three-armed study over a four year period conducted in British Columbia. It will recruit 33,000 women aged 25-65 through the province's population based cervical cancer screening program. Control arm: LBC at entry and two years, and combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases; Two Year Safety Check arm: hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives; Four Year Intervention Arm: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive cases To date, 6150 participants have a completed sample and epidemiologic questionnaire. Of the 2019 women enrolled in the control arm, 1908 (94.5%) were cytology negative. Women aged 25-29 had the highest rates of HSIL (1.4%). In the safety arm 92.2% of women were hr-HPV negative, with the highest rate of hr-HPV positivity found in 25-29 year old women (23.5%). Similar results were obtained in the intervention arm HPV FOCAL is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer within a population-based cervical cancer screening program. International Standard Randomised Controlled Trial Number Register, ISRCTN79347302